NCT01038778 2026-03-18
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
20 trialsNCT01684397 2026-02-27
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT04626479 2026-02-12
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT05468697 2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT02473536 2026-01-16
Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC
University of Texas Southwestern Medical Center
Phase 1/2 Active not recruiting
NCT05501054 2026-01-14
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05826600 2026-01-06
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
iOmx Therapeutics AG
Phase 1/2 Active not recruiting
NCT05363631 2025-12-10
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
University of Iowa
Phase 1/2 Active not recruiting
NCT05661955 2025-11-21
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
BeOne Medicines
Phase 1/2 Active not recruiting
NCT04074967 2025-11-06
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT06245915 2025-09-22
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Arsenal Biosciences, Inc.
Phase 1/2 Active not recruiting
NCT03647163 2025-09-16
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Vyriad, Inc.
Phase 1/2 Active not recruiting
NCT06127238 2025-08-24
Study of ST-1898 in Advanced Renal Cell Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 1/2 Active not recruiting
NCT06480565 2025-08-15
A Phase 1/2 Trial of ADI-270 in ccRCC
Adicet Therapeutics
Phase 1/2 Active not recruiting
NCT04626518 2025-07-25
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05128487 2024-11-25
A Study of NDI 1150-101 in Patients With Solid Tumors
Nimbus Therapeutics
Phase 1/2 Active not recruiting
NCT05620134 2024-10-15
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Phase 1/2 Active not recruiting
NCT04913337 2024-10-02
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
Phase 1/2 Active not recruiting
NCT03294083 2022-10-27
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
SillaJen, Inc.
Phase 1/2 Active not recruiting